Vlachaki Efthimia, Tselios Konstantinos, Perifanis Vasilios, Tsatra Ioanna, Tsayas Ioannis
Thalassemic Unit, Hippokration General Hospital, Thessaloniki, Greece.
Clin Rheumatol. 2008 Nov;27(11):1459-61. doi: 10.1007/s10067-008-0969-y. Epub 2008 Jul 29.
Deferiprone (DFP), the first oral iron chelator, has been used in patients with beta-thalassemia major to reduce serum ferritin levels and total iron burden, leading to decreased cardiac iron levels. Major side effects include embryotoxicity, agranulocytosis, zinc deficiency and gastrointestinal disorders, while arthropathy is rarely reported. Herein, we present a 29-year-old male patient with beta-thalassemia major, who developed severe arthritis of both knees while under deferiprone therapy. Arthritis was managed successfully with non-steroid antiinflammatory drugs after DFP withdrawal.
去铁酮（DFP）是第一种口服铁螯合剂，已用于重型β地中海贫血患者，以降低血清铁蛋白水平和总铁负荷，从而降低心脏铁水平。主要副作用包括胚胎毒性、粒细胞缺乏症、锌缺乏和胃肠道疾病，而关节病很少有报道。在此，我们报告一名29岁的重型β地中海贫血男性患者，他在接受去铁酮治疗时出现了双膝严重关节炎。停用DFP后，使用非甾体抗炎药成功控制了关节炎。
